GLASF
Price
$6.27
Change
-$0.01 (-0.16%)
Updated
Dec 3 closing price
Capitalization
505.63M
104 days until earnings call
Intraday BUY SELL Signals
MEDIF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Dec 3 closing price
Capitalization
19.58M
Intraday BUY SELL Signals
Interact to see
Advertisement

GLASF vs MEDIF

Header iconGLASF vs MEDIF Comparison
Open Charts GLASF vs MEDIFBanner chart's image
Glass House Brands
Price$6.27
Change-$0.01 (-0.16%)
Volume$118.5K
Capitalization505.63M
Medipharm Labs
Price$0.05
Change-$0.00 (-0.00%)
Volume$25.39K
Capitalization19.58M
GLASF vs MEDIF Comparison Chart in %
GLASF
Daily Signal:
Gain/Loss:
MEDIF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GLASF vs. MEDIF commentary
Dec 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLASF is a Hold and MEDIF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 05, 2025
Stock price -- (GLASF: $6.27 vs. MEDIF: $0.05)
Brand notoriety: GLASF and MEDIF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: GLASF: 62% vs. MEDIF: 12%
Market capitalization -- GLASF: $505.63M vs. MEDIF: $19.58M
GLASF [@Pharmaceuticals: Generic] is valued at $505.63M. MEDIF’s [@Pharmaceuticals: Generic] market capitalization is $19.58M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLASF’s FA Score shows that 0 FA rating(s) are green whileMEDIF’s FA Score has 0 green FA rating(s).

  • GLASF’s FA Score: 0 green, 5 red.
  • MEDIF’s FA Score: 0 green, 5 red.
According to our system of comparison, GLASF is a better buy in the long-term than MEDIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLASF’s TA Score shows that 6 TA indicator(s) are bullish while MEDIF’s TA Score has 4 bullish TA indicator(s).

  • GLASF’s TA Score: 6 bullish, 4 bearish.
  • MEDIF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GLASF is a better buy in the short-term than MEDIF.

Price Growth

GLASF (@Pharmaceuticals: Generic) experienced а -0.95% price change this week, while MEDIF (@Pharmaceuticals: Generic) price change was +7.76% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.75%. For the same industry, the average monthly price growth was +0.65%, and the average quarterly price growth was +19.08%.

Reported Earning Dates

GLASF is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.75% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLASF($506M) has a higher market cap than MEDIF($19.6M). MEDIF YTD gains are higher at: 10.896 vs. GLASF (8.103). GLASF has higher annual earnings (EBITDA): 49M vs. MEDIF (-6.45M). GLASF has more cash in the bank: 40.7M vs. MEDIF (10.4M). MEDIF has less debt than GLASF: MEDIF (542K) vs GLASF (72.8M). GLASF has higher revenues than MEDIF: GLASF (222M) vs MEDIF (44.5M).
GLASFMEDIFGLASF / MEDIF
Capitalization506M19.6M2,582%
EBITDA49M-6.45M-760%
Gain YTD8.10310.89674%
P/E Ratio513.07N/A-
Revenue222M44.5M499%
Total Cash40.7M10.4M391%
Total Debt72.8M542K13,432%
FUNDAMENTALS RATINGS
GLASF vs MEDIF: Fundamental Ratings
GLASF
MEDIF
OUTLOOK RATING
1..100
6566
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9395
PRICE GROWTH RATING
1..100
6286
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1755

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEDIF's Valuation (91) in the null industry is in the same range as GLASF (93). This means that MEDIF’s stock grew similarly to GLASF’s over the last 12 months.

MEDIF's Profit vs Risk Rating (100) in the null industry is in the same range as GLASF (100). This means that MEDIF’s stock grew similarly to GLASF’s over the last 12 months.

GLASF's SMR Rating (93) in the null industry is in the same range as MEDIF (95). This means that GLASF’s stock grew similarly to MEDIF’s over the last 12 months.

GLASF's Price Growth Rating (62) in the null industry is in the same range as MEDIF (86). This means that GLASF’s stock grew similarly to MEDIF’s over the last 12 months.

GLASF's P/E Growth Rating (100) in the null industry is in the same range as MEDIF (100). This means that GLASF’s stock grew similarly to MEDIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLASFMEDIF
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GLASF
Daily Signal:
Gain/Loss:
MEDIF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HUIPF0.050.01
+25.00%
Hydrogen Utopia International PLC
ACSYF0.87N/A
N/A
Accsys Technologies Plc.
TVAHF21.25N/A
N/A
TV Asahi Holdings Corp.
AFSIP15.20N/A
N/A
AmTrust Financial Services, Inc.
LYSCF9.70-0.23
-2.27%
Lynas Rare Earths Limited

GLASF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLASF has been loosely correlated with TSNDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if GLASF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLASF
1D Price
Change %
GLASF100%
-0.22%
TSNDF - GLASF
63%
Loosely correlated
+11.96%
GTBIF - GLASF
62%
Loosely correlated
+0.78%
TCNNF - GLASF
60%
Loosely correlated
-1.00%
CURLF - GLASF
57%
Loosely correlated
+4.72%
CRLBF - GLASF
57%
Loosely correlated
-2.43%
More

MEDIF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEDIF has been loosely correlated with CGC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDIF jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDIF
1D Price
Change %
MEDIF100%
-7.66%
CGC - MEDIF
36%
Loosely correlated
+4.50%
TLRY - MEDIF
28%
Poorly correlated
-8.43%
ACB - MEDIF
24%
Poorly correlated
+1.34%
AAWH - MEDIF
24%
Poorly correlated
-9.15%
GLASF - MEDIF
24%
Poorly correlated
-0.22%
More